Graematter Revenue and Competitors

Ballwin, MO USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Graematter's estimated annual revenue is currently $775k per year.(i)
  • Graematter's estimated revenue per employee is $155,000

Employee Data

  • Graematter has 5 Employees.(i)
  • Graematter grew their employee count by -17% last year.

Graematter's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$79.1M5106%N/AN/A
#2
$1.1M717%N/AN/A
#3
$4.2M27-32%N/AN/A
#4
$2M1330%N/AN/A
#5
$4.3M284%N/AN/A
#6
$0.9M60%N/AN/A
#7
$5M323%N/AN/A
#8
$3.7M244%N/AN/A
#9
$0.3M40%N/AN/A
#10
$6M3950%N/AN/A
Add Company

What Is Graematter?

Graematter provides regulatory intelligence knowledge tools, research services, and expert consulting in the medical products industry. Supported by experienced professionals and a patented, proprietary knowledge management system, you can know what there is to know about medical products - the regulatory path, testing performed, adverse events, the sponsoring company, and the people who played a part in the process. Graematter's Regulatory Intelligence System A comprehensive, patented repository of regulatory information in the medical products industry. Soon to be accessible through subscription. Increase your efficiency and accuracy when developing true Regulatory Intelligence. Founder Graematter was founded by Melissa Walker, MS, RAC, FRAPS. An accomplished senior executive with over 25 years of experience, Melissa has proven expertise in business management, regulatory affairs, quality systems, healthcare compliance, and clinical research, Melissa founded Graematter to ease the burden of collecting and understanding regulatory intelligence.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$775k

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M5-80%N/A
#2
$0.6M8N/AN/A
#3
$1M1220%N/A
#4
$1.8M19-5%N/A
#5
$3.8M20-77%N/A